A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Aromatase Inhibitor|DRUG: Induction Chemotherapy
Sponsor: Hoffmann-La Roche